Redsense receives first order from distribution partner in the Netherlands
Redsense Medical announces that Dirinco, the company’s distribution partner in the Netherlands, concluded a successful initial evaluation of the Redsense blood leakage alarm system directly connected to a Nikkiso DBB-EXA dialysis machine.
As a result of the successful evaluation, Dirinco’s reference clinic will now also broaden the evaluation to include nocturnal dialysis treatments in clinic.
The first order is valued at approximately 60 KSEK.
“I see strong initiative from Dirinco’s side and they have a solid customer base and cooperation with key reference clinics. The successful evaluation builds a strong start to our partnership”, says Patrik Byhmer, CEO of Redsense Medical.
For more information, please contact
Patrik Byhmer, CEO Redsense Medical AB (publ)
Telephone: +46 (0) 35 - 10 60 30
About Redsense Medical
Redsense Medical is a corporate group with operations mainly in Europe and the United States. The company has developed the Redsense system, a medical technology product used for monitoring and alarm in the case of blood leakage in connection with hemodialysis. Redsense solves one of the most serious remaining safety problems within hemodialysis – to quickly detect venous needle dislodgement and catheter leakage and minimizing blood leakage. The system consists of a patented fiber optic sensor, designed for either venous needle or central venous catheter, which is connected to an alarm unit. The company has also developed an internationally standardized direct connection enabling compatible dialysis machines to stop the blood flow automatically when blood leakage occurs. From the very start, the development of the company's technology has been based on the demands and safety requirements of healthcare providers in the dialysis sector.
Redsense Medical’s stock is listed on Nasdaq First North with ticket REDS. Erik Penser Bank is the company’sCertified Adviser.
This information is such information that Redsense Medical AB (publ) is obligated to publish in compliance with the EU market abuse regulation. This information was provided, through the above contact, for publication on October 9, 2018.